Perioperative outcomes and platinum resistant recurrence in patients undergoing systematic, protocol-based, total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer: results of the TORPEDO study-Reference-Cited by-同舟云学术

Perioperative outcomes and platinum resistant recurrence in patients undergoing systematic, protocol-based, total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer: results of the TORPEDO study

Published:2024 Issue:4 Volume:35 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Bhatt Aditi¹^ORCID,Sinukumar Snita²^ORCID,Damodaran Dileep³^ORCID,Parikh Loma⁴^ORCID,Goswami Gaurav⁵^ORCID,Mehta Sanket⁶^ORCID,Kammar Praveen⁶^ORCID

Affiliation:

1. Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India.

2. Department of Surgical Oncology, Jehangir Hospital, Pune, India.

3. Department of Surgical Oncology, MVR Cancer Center, Calicut, India.

4. Department of Pathology, Zydus Hospital, Ahmedabad, India.

5. Department of Radiology, Zydus Hospital, Ahmedabad, India.

6. Department of Surgical Oncology, Saifee Hospital, Mumbai, India.

Publisher

XMLink

Link

https://ejgo.org/pdf/10.3802/jgo.2024.35.e95

Reference33 articles.

1. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

2. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

3. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)

4. Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study

5. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer